Sponsored by
We’re excited to see these Phase 1 study results now published in Neuro-Oncology Advances.
The drug appeared safe and generally well tolerated, and the median overall survival was about 16 months, which compares favorably to historical outcomes in recurrent glioblastoma. While this is a small, non-randomized trial of only 22 analyzed patients, thes results are encouraging for a Phase 1 study in this setting.
Most patients still followed the expected course of progression over time, but five of the 22 included patients are still alive. Four of those are beyond 18 months, and two of them are at 31 and 39 months since starting treatment with gallium maltolate.
We helped fund an expanded access program for oral gallium maltolate, and we’re encouraged to see it is now expected to open to about 20 additional patients, giving more families access while the research continues.